Catherine Longworth is a reporter covering commercial and R&D developments in the medtech industry. A graduate of St. George's, University of London, Catherine holds a BSc in Biomedical Science. Before joining Informa, she worked in the editorial team at Pharmaceutical Press, the publishing division of the Royal Pharmaceutical Society, where she wrote and edited for a number of pharmaceutical publications. After gaining experience in the world of scientific publishing, Catherine took the leap to study a postgraduate qualification in journalism. During the course, she carried out placements with local London newspapers, writing general news and building her portfolio by reporting on a wide range of current affairs such as the European migrant crisis, political protests and the London mayoral election. Catherine is passionate about human rights and is fascinated by the innovative nature of the medtech industry and the healthcare advances that have the greatest benefit to mankind. She lives in London and loves music, arts, travel, writing, reading and is always happy to receive recommendations for books or places to travel!
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Catherine Longworth
On this week's podcast, Medtech Insight's Catherine Longworth chats with Marion Webb about some key takeaways from this year's JP Morgan Healthcare Conference. That includes a Q&A with Smith & Nephew's new CEO Namal Nawana on his growth strategy for the British medtech giant, new partnership announcements between medtech and tech companies, and trends in digital health.
Abbott has exercised an option to buy Cephea Valve Technologies, developer of a minimally-invasive replacement heart valve, for an undisclosed sum.
GE Healthcare is making a bid to become the leader in precision medicine by collaborating with Vanderbilt University Medical Center to develop AI-powered diagnostic tools for cancer care.
Neuromodulation firm Nexstim will launch its SmartFocus TMS system for treating major depressive disorder (MDD) in Canada after signing an exclusive agreement with distributor Canada Health Solutions CHS.